Repositioning Candidate Details
| Candidate ID: | R1122 |
| Source ID: | DB07565 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Chloramphenicol succinate |
| Synonyms: | Chloramphenicol hemisuccinate |
| Molecular Formula: | C15H16Cl2N2O8 |
| SMILES: | O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O |
| Structure: |
|
| DrugBank Description: | Chloramphenicol succinate is an ester prodrug of . Chloramphenicol is a bacteriostatic antibiotic. Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias. Chloramphenicol succinate was granted FDA approval on 20 February 1959. |
| CAS Number: | 3544-94-3 |
| Molecular Weight: | 423.202 |
| DrugBank Indication: | Chloramphenicol succinate is indicated to treat serious and susceptible bacterial infections where less dangerous drugs are ineffective or contraindicated. |
| DrugBank Pharmacology: | Chloramphenicol succinate is a prodrug of chloramphenicol, which binds to bacterial ribosomes and prevents translation. It has a narrow therapeutic index and a moderate duration of action. Patients should be counselled regarding the risk of serious fatal blood dyscrasias. |
| DrugBank MoA: | Chloramphenicol succinate is hydrolyzed into the active chloramphenicol. Chloramphenicol resembles uridine-5'-phosphate. It binds to the residues A2451 and A2452 in the 23S rRNA of the 50S ribosomal subunit of _E. coli_, which prevents translation. |
| Targets: | Dr hemagglutinin structural subunit inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|